Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
- PMID: 35005993
- PMCID: PMC8769132
- DOI: 10.1200/PO.21.00400
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
Conflict of interest statement
Figures



Similar articles
-
Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.Pediatr Blood Cancer. 2021 Sep;68(9):e29122. doi: 10.1002/pbc.29122. Epub 2021 May 21. Pediatr Blood Cancer. 2021. PMID: 34019333 No abstract available.
-
VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.J Thorac Oncol. 2018 May;13(5):e72-e74. doi: 10.1016/j.jtho.2017.11.134. J Thorac Oncol. 2018. PMID: 29703539 No abstract available.
-
Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.J Cell Mol Med. 2021 Oct;25(19):9476-9481. doi: 10.1111/jcmm.16897. Epub 2021 Sep 19. J Cell Mol Med. 2021. PMID: 34541785 Free PMC article. Review.
-
EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.Jpn J Clin Oncol. 2020 Dec 16;50(12):1470-1474. doi: 10.1093/jjco/hyaa156. Jpn J Clin Oncol. 2020. PMID: 32845005
-
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14. Future Oncol. 2018. PMID: 29536761 Review.
Cited by
-
Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies-ALK and PIK3CA.Front Oncol. 2024 Nov 26;14:1462930. doi: 10.3389/fonc.2024.1462930. eCollection 2024. Front Oncol. 2024. PMID: 39659799 Free PMC article.
-
New treatment insights into pancreatic acinar cell carcinoma: case report and literature review.Front Oncol. 2023 Jul 3;13:1210064. doi: 10.3389/fonc.2023.1210064. eCollection 2023. Front Oncol. 2023. PMID: 37465113 Free PMC article. Review.
-
Pediatric pancreatic acinar cell carcinoma with a non-canonical BRAF-KMT2C fusion and a classic SND1-BRAF fusion: a case report and literature review.BMC Pediatr. 2025 Jan 24;25(1):57. doi: 10.1186/s12887-024-05378-7. BMC Pediatr. 2025. PMID: 39856649 Free PMC article. Review.
-
A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Ther Adv Med Oncol. 2024 Jul 26;16:17588359241265213. doi: 10.1177/17588359241265213. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39072242 Free PMC article. Review.
-
Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired ALK Rearrangement.JCO Precis Oncol. 2023 Sep;7:e2300287. doi: 10.1200/PO.23.00287. JCO Precis Oncol. 2023. PMID: 38096470 Free PMC article. No abstract available.
References
-
- Melisi D, Calvetti L, Frizziero M, et al. : Pancreatic cancer: Systemic combination therapies for a heterogeneous disease. Curr Pharm Des 20:6660-6669, 2014 - PubMed
-
- Wisnoski NC, Townsend CM Jr, Nealon WH, et al. : 672 patients with acinar cell carcinoma of the pancreas: A population-based comparison to pancreatic adenocarcinoma. Surgery 144:141-148, 2008 - PubMed
-
- Holen KD, Klimstra DS, Hummer A, et al. : Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20:4673-4678, 2002 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical